TMPRSS2-ERG Fusion Promotes Recruitment of Regulatory T cells and Tumor Growth in Prostate Cancer. 2018

Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
Department of Urology, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

This study was designed to examine the effect of transmembrane protease serine 2 ETS-related gene (TMPRSS2-ERG) fusion on regulatory T cells and tumor growth in prostate cancer, which may provide a new potential therapeutic direction for PCa. The effect of TMPRSS2-ERG fusion on the migration of Treg cells and tumor growth in a mouse model was investigated in vitro and in vivo. TMPRSS2-ERG fusion in biopsy tissues was performed by fluorescence in situ hybridization and the expression of ERG and Forkhead box P3 was detected by gel electrophoresis, real-time quantitative reverse transcription polymerase chain reaction and Western blot. Enzyme-linked immunosorbent assay and flow cytometry were used to analyze transforming growth factor β levels and the number of regulatory T cells, respectively. Finally, the infiltration of regulatory T cells was analyzed by Forkhead box P3 immunohistochemistry. Fluorescence in situ hybridization analysis showed that the TMPRSS2-ERG fusion gene was positive in prostate cancer and that the messenger RNA and protein expression of ERG were significantly up-regulated in prostate cancer biopsy tissues. Furthermore, the number of regulatory T cells and the levels of Forkhead box P3 and transforming growth factor β were significantly increased in prostate cancer. TMPRSS2-ERG fusion increased the migration and activation of regulatory T cells in vitro and promoted subcutaneous tumor size and regulatory T cells infiltration in mouse models. TMPRSS2-ERG fusion can regulate the recruitment and infiltration of regulatory T cells to promote tumor growth in prostate cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078722 PC-3 Cells An epithelial cell line initiated from a human bone metastasis of a grade IV prostatic ADENOCARCINOMA. Human Prostatic Carcinoma Cell Line PC3,PC-3 (Human Prostatic Carcinoma) Cell Line,PC-3 Cell Line,PC3 Cell Line,PC3 Cells,Cell Line, PC-3,Cell Line, PC3,Cells, PC-3,Cells, PC3,Line, PC-3 Cell,PC 3 Cell Line,PC 3 Cells,PC-3 Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015514 Oncogene Proteins, Fusion The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin. Chimeric Oncogene Proteins,Chimeric Proteins, Oncogene,Fusion Proteins, Oncogene,Oncogene Fusion Proteins,Oncogene Proteins, Chimeric,Fusion Oncogene Proteins,Oncogene Chimeric Proteins,Proteins, Chimeric Oncogene,Proteins, Fusion Oncogene,Proteins, Oncogene Chimeric,Proteins, Oncogene Fusion
D046888 Tissue Array Analysis The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips. Cell Array Analysis,Cell Microarray Analysis,Tissue Microarray Analysis,Analyses, Cell Array,Analyses, Cell Microarray,Analyses, Tissue Array,Analyses, Tissue Microarray,Analysis, Cell Array,Analysis, Cell Microarray,Analysis, Tissue Array,Analysis, Tissue Microarray,Array Analyses, Cell,Array Analyses, Tissue,Array Analysis, Cell,Array Analysis, Tissue,Cell Array Analyses,Cell Microarray Analyses,Microarray Analyses, Cell,Microarray Analyses, Tissue,Microarray Analysis, Cell,Microarray Analysis, Tissue,Tissue Array Analyses,Tissue Microarray Analyses
D050378 T-Lymphocytes, Regulatory CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. Regulatory T Cell,Regulatory T-Cell,Regulatory T-Lymphocyte,Regulatory T-Lymphocytes,Suppressor T-Lymphocytes, Naturally-Occurring,T-Cells, Regulatory,Th3 Cells,Tr1 Cell,Treg Cell,Regulatory T-Cells,Suppressor T-Cells, Naturally-Occurring,Tr1 Cells,Treg Cells,Cell, Regulatory T,Cell, Th3,Cell, Tr1,Cell, Treg,Cells, Regulatory T,Cells, Th3,Cells, Tr1,Cells, Treg,Naturally-Occurring Suppressor T-Cell,Naturally-Occurring Suppressor T-Cells,Naturally-Occurring Suppressor T-Lymphocyte,Naturally-Occurring Suppressor T-Lymphocytes,Regulatory T Cells,Regulatory T Lymphocyte,Regulatory T Lymphocytes,Suppressor T Cells, Naturally Occurring,Suppressor T Lymphocytes, Naturally Occurring,Suppressor T-Cell, Naturally-Occurring,Suppressor T-Lymphocyte, Naturally-Occurring,T Cell, Regulatory,T Cells, Regulatory,T Lymphocytes, Regulatory,T-Cell, Naturally-Occurring Suppressor,T-Cells, Naturally-Occurring Suppressor,T-Lymphocyte, Regulatory,Th3 Cell

Related Publications

Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
February 2017, Oncotarget,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
December 2014, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
March 2010, Prostate cancer and prostatic diseases,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
May 2008, Asian journal of andrology,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
February 2021, The Prostate,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
January 2017, Frontiers in endocrinology,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
July 2010, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
May 2007, The Journal of pathology,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
May 2015, American journal of epidemiology,
Lei Shan, and Tongyu Ji, and Xiang Su, and Qichao Shao, and Tao Du, and Shilong Zhang
April 2012, Journal of cancer science & therapy,
Copied contents to your clipboard!